13F Confidential Treatment: How Funds Hide Positions

What confidential treatment actually is

Rule 13f-1 requires any institutional investment manager with discretion over $100 million or more in covered US equities to report its long positions within 45 days of each quarter end. That report becomes public the moment EDGAR accepts it, which creates an obvious problem for a manager partway through a large accumulation: the filing telegraphs the trade, and anyone who front-runs the rest of the program gets paid at the manager's (and its clients') expense.

Congress anticipated this. Section 13(f) of the Securities Exchange Act gives the SEC authority to delay or prevent public disclosure of 13F information where it judges that necessary or appropriate. In practice that authority is exercised through a confidential treatment request: the manager asks permission to omit specific holdings from the public report, almost always on the grounds that disclosure would reveal an ongoing acquisition or disposition program and cause substantial competitive harm.

Two points are worth fixing in your head before going further. First, this is position-level, not filer-level. The rest of the 13F still goes public on the normal schedule, with all the usual structure covered in how to read a 13F filing. Second, the information is delayed, never destroyed. Granted requests are time-limited, and the omitted positions eventually appear in an amendment. That amendment is exactly where careful readers of filing data look, and it is why confidential treatment is better understood as a timing tool than a cloak.

How the SEC decides a request

The mechanics are deliberately unglamorous. On or before the 45-day deadline, the manager files its public 13F minus the omitted positions, states on the form that confidential information has been omitted and filed separately with the Commission, and sends the omitted holdings plus a written justification to the SEC through a non-public channel.

The legal standard borrows from the trade-secret exemption in freedom-of-information law: the manager must show that the omitted information is the kind it actually keeps private and that releasing it would cause real, demonstrable competitive harm. A generic preference for secrecy fails. The classic winning argument is a specific, ongoing program: we are partway through building a position, disclosure would reveal the program to the market, and the resulting price impact would damage clients. The SEC's own Form 13F FAQ sketches the framework, and the staff reviews each request on its facts rather than rubber-stamping.

Grants are typically narrow and time-limited, commonly up to a year, with extensions possible but never assumed. Denials are not rare. The SEC has historically pushed back hard on requests it reads as boilerplate, and a denied manager must promptly amend its public filing to disclose what it tried to withhold, which can be more conspicuous than ordinary disclosure would have been. Academic work on the subject has generally found that confidentially treated holdings skew toward informed, price-sensitive accumulation, which is consistent with how the exemption is supposed to work and explains why the staff polices it. For plain-language background on 13F reports generally, Investor.gov's overview is the canonical reference.

What confidential treatment can and cannot hide

Confidential treatment applies to one document: the quarterly 13F. Every other ownership-disclosure trigger keeps running on its own clock, and several of those clocks are far faster.

The interactions matter more than the rule itself. A manager quietly accumulating under 13F confidential treatment still trips Schedule 13D within 5 business days if it crosses 5% of a company with control intent, and corporate insiders keep reporting their own trades on Form 4 within 2 business days regardless of what any fund is doing. We track 51,000+ insider transactions alongside the 13F universe for exactly that kind of cross-checking. The full comparison of these forms lives in 13F vs 13D vs 13G vs Form 4, and the 2026 quarterly calendar (Feb 17, May 15, Aug 14, Nov 16) is in 13F filing deadlines 2026.

So the realistic use case is narrow: a sub-5% or passively held position in a liquid large cap, built over one to a few quarters, by a manager whose name alone moves prices. Which points directly at the most famous user.

Famous accumulations behind the curtain

Berkshire Hathaway is the canonical example. Warren Buffett has been openly hostile to telegraphing trades, and Berkshire's filings have repeatedly carried the omission notice while multibillion dollar stakes were being assembled. Widely reported cases include the large technology accumulation of 2011 (the IBM stake stayed off public 13Fs for quarters while it was built) and, more recently, an insurance stake revealed in 2024 after several quarters under confidential treatment, by which point the buying was finished. In each case the position surfaced through amendments fully formed, and the market reaction landed all at once on the reveal rather than dripping out during the accumulation. The current public snapshot of that portfolio is in our Berkshire Q1 2026 13F breakdown.

It is not a Berkshire-only tool. Merger arbitrage and event-driven shops have historically cited open risk positions in their requests, since a public 13F can effectively publish their book mid-deal. And the SEC's skepticism cuts against everyone: by public reports it has denied requests from even the most prominent managers over the years, forcing amendments that disclosed the withheld names.

The honest framing for anyone consuming 13F data: confidential treatment is rare, scrutinized, and temporary, but when it is in play it means the most information-rich positions in a filing are precisely the ones you cannot see yet. Treat any single quarter's 13F as a lower bound on what a manager owns, not a census.

How hidden positions surface in the data

The reveal has a signature, and it is mechanical enough for an agent to watch for.

First, the omission notice: the public 13F itself discloses that confidential information was omitted and filed separately. You learn that something is hidden, not what. Second, the retroactive amendment: when treatment lapses or is denied, the manager files a 13F/A that adds holdings to a quarter that already closed. A position appearing fully sized in an amendment to a past period, rather than growing across consecutive original filings, is the fingerprint of confidential treatment. Third, the cross-quarter jump: a stake that debuts enormous, with no prior accumulation visible, often had its early innings withheld.

This is why amendment handling is not optional in 13F data. Arkolith resolves original filings and amendments into a single superseded view, so a confidential reveal updates the historical quarters it actually belongs to, and every datapoint carries provenance back to its SEC accession number, which matters when an agent needs to prove where a number came from (see how accurate is 13F data for the broader error taxonomy). The Q1 2026 dataset behind that view covers 1,824 institutional filers, 1.87 million long positions, and $53.7 trillion in reported value.

If you want to watch this programmatically:

# Resolve a manager to its CIK
curl -H "Authorization: Bearer YOUR_KEY" "https://arkolith.com/api/v1/search?q=berkshire"

# Pull holdings with amendments already superseded into the quarter view
curl -H "Authorization: Bearer YOUR_KEY" "https://arkolith.com/api/v1/funds/1067983/holdings"

# Browse the tracked institutional universe
curl -H "Authorization: Bearer YOUR_KEY" "https://arkolith.com/api/v1/funds"

The quickstart covers minting a key, and the human-browsable version of the same universe lives at /investors.

Frequently asked questions about 13F confidential treatment

How long can a fund keep a 13F position confidential?

Grants are time-limited, commonly up to one year, and the SEC can approve shorter windows or extend on a fresh showing of continued need. When the period ends, the manager must file an amendment that makes the omitted positions public. The information is delayed, never permanently exempt.

Can you tell when a 13F omits confidential positions?

Often, yes. The public filing must state that confidential information has been omitted and filed separately with the Commission, so the existence of a hidden position is visible even though its identity is not. The other tell is retrospective: a later 13F/A that adds fully formed holdings to a previously filed quarter.

Does confidential treatment delay Schedule 13D or Form 4 filings?

No. It applies only to Form 13F. Crossing 5% of a company's shares with control intent still triggers Schedule 13D within 5 business days, and corporate insiders still report their own trades on Form 4 within 2 business days.

What happens when a confidential treatment request is denied?

The manager must promptly amend its public 13F to disclose the withheld holdings. By public reports the SEC has denied requests from even the most prominent filers, and the forced amendment often attracts more attention than routine quarterly disclosure would have. That asymmetry is one reason managers use the mechanism sparingly.

This article explains public filings and data concepts. It is not investment advice.